112 related articles for article (PubMed ID: 8361025)
21. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
22. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products.
Kogan AE; Mukharyamova KS; Bereznikova AV; Filatov VL; Koshkina EV; Bloshchitsyna MN; Katrukha AG
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):542-50. PubMed ID: 26656897
[TBL] [Abstract][Full Text] [Related]
24. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
vanDeWater L; Carr JM; Aronson D; McDonagh J
Blood; 1986 May; 67(5):1468-73. PubMed ID: 2938648
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of fibrin degradation products and d-dimer levels as biomarkers that reflect the severity of trauma.
Hagiwara S; Oshima K; Aoki M; Murata M; Ishihara K; Kaneko M; Furukawa K; Nakamura T; Ohyama Y; Tamura J
J Trauma Acute Care Surg; 2013 May; 74(5):1275-8. PubMed ID: 23609278
[TBL] [Abstract][Full Text] [Related]
26. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
Gando S; Hayakawa M; Sawamura A; Hoshino H; Oshiro A; Kubota N; Jesmin S
Thromb Res; 2007; 121(1):67-73. PubMed ID: 17397908
[TBL] [Abstract][Full Text] [Related]
27. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
[TBL] [Abstract][Full Text] [Related]
28. Fibrinolysis in idiopathic menorrhagia.
Bisht D; Gupta SC; Kaushik S; Ganguli G; Mital VP
Indian J Pathol Microbiol; 1991 Jul; 34(3):200-2. PubMed ID: 1818856
[TBL] [Abstract][Full Text] [Related]
29. [The levels of FDP, FDP-E and D-dimer in patients with rheumatoid arthritis].
Nakashima M; Aoyagi T; Aratake K; Kawabe Y; Eguchi K
Ryumachi; 1998 Dec; 38(6):793-800. PubMed ID: 10047717
[TBL] [Abstract][Full Text] [Related]
30. Measurement of urinary fibrin/fibrinogen degradation products by latex photometric immunoassay.
Kaizu K; Ito Y; Uriu K; Eto S
Nihon Jinzo Gakkai Shi; 1993 Jan; 35(1):23-8. PubMed ID: 8336396
[TBL] [Abstract][Full Text] [Related]
31. Unreliability of current serum fibrin degradation product (FDP) assays.
Gaffney PJ; Perry MJ
Thromb Haemost; 1985 Jun; 53(3):301-2. PubMed ID: 3901388
[TBL] [Abstract][Full Text] [Related]
32. Electrophoretic demonstration of high molecular weight fibrin degradation products persisting in chronic subdural hematomas.
Toyosawa M; Kashiwagi S; Pei W; Fujisawa H; Ito H; Nakamura K
Electrophoresis; 1997 Jan; 18(1):118-21. PubMed ID: 9059832
[TBL] [Abstract][Full Text] [Related]
33. [Study on the fibrin fibrinogen degradation products levels and it's significance in the phlegm of the patients with chronic cor pulmonale through monoclonal antibodies].
He GZ
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Jun; 13(3):154-6, 191. PubMed ID: 2249318
[TBL] [Abstract][Full Text] [Related]
34. [Immunoenzyme determination of fibrin-fibrinogen degradation product levels in acute myocardial infarct patients].
Grinshteĭn IA; Ignashenkova GV; Kitaev MI
Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):18-21. PubMed ID: 3300697
[TBL] [Abstract][Full Text] [Related]
35. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
Agarwal S; Joyner KA; Swaim MW
Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
[TBL] [Abstract][Full Text] [Related]
36. Comparisons of hemagglutination inhibition, staphylococcal clumping, and latex agglutination tests for canine fibrinolytic degradation products.
Chen JP; Williams TK; Legendre AM
Am J Vet Res; 1981 Dec; 42(12):2049-52. PubMed ID: 7340573
[TBL] [Abstract][Full Text] [Related]
37. [Fibrin degradation products (FDP) and fibrinolytic activity of blood in various acute and chronic diseases].
Kotschy M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):425-30. PubMed ID: 63429
[No Abstract] [Full Text] [Related]
38. [Relation between fibrin/fibrinogen degradation products in malignant fluids and the fibrinolytic activity of the peritoneum].
Takahashi M; Yoshida K; Kano K; Machida T; Nakamura Y; Miura Y; Miura N; Kanno S
Gan No Rinsho; 1986 Dec; 32(15):1945-9. PubMed ID: 3806965
[TBL] [Abstract][Full Text] [Related]
39. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
[TBL] [Abstract][Full Text] [Related]
40. [Preparation and separation of milligram amounts of canine fibrin(ogen) degradation products (fdp) X, Y, D and E].
Wolling H; Mischke R
Berl Munch Tierarztl Wochenschr; 1995 Nov; 108(11):421-6. PubMed ID: 8593135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
